

Amendments to the Claims

1-28. (Canceled)

¹
~~28~~. (Currently amended) A method of treating cardiac hypertrophy comprising administering to a patient diagnosed with pressure overload induced $\text{PGF}_{2\alpha}$ -associated cardiac hypertrophy a therapeutically effective amount of interferon gamma ($\text{IFN-}\gamma$).

²
~~30~~. (Previously presented) The method of claim ~~28~~¹ wherein said patient is human.

31. (Canceled)

³
~~32~~. (Previously presented) The method of claim ~~30~~² wherein said $\text{IFN-}\gamma$ is rh $\text{IFN-}\gamma$ -1b.

33-39 (Canceled)

⁴
~~40~~. (Previously presented) The method of claim ~~30~~² wherein said $\text{IFN-}\gamma$ is administered in combination with at least one further therapeutic agent used for the treatment of cardiac hypertrophy or a heart disease resulting in cardiac hypertrophy.

⁵
~~41~~. (Previously presented) The method of claim ~~40~~⁴ wherein said further therapeutic agent is selected from the group consisting of β -adrenergic-blocking agents, verapamil, diltiazem, and diltiazem.

⁶
~~42~~. (Previously presented) The method of claim ~~41~~⁵ wherein said β -adrenergic-blocking agent is carvedilol, propranolol, metoprolol, timolol, alprenolol or terbutaline.

⁷
~~43~~. (Previously presented) The method of claim ~~40~~⁴ wherein said $\text{IFN-}\gamma$ is administered in combination with an antihypertensive drug.

⁸
~~44~~. (Previously presented) The method of claim ~~40~~⁴ wherein said IFN- γ is administered with an ACE-inhibitor.

⁹
~~45~~. (Previously presented) The method of claim ~~40~~⁴ wherein said IFN- γ is administered with an endothelin receptor antagonist.

¹⁰
~~46~~. (Previously presented) The method of claim ~~40~~⁴ wherein said IFN- γ is administered following the administration of a thrombolytic agent.

¹¹
~~47~~. (Previously presented) The method of claim ~~46~~¹⁰ wherein said thrombolytic agent is recombinant human tissue plasminogen activator (rht-PA).

¹²
~~48~~. (Previously presented) The method of claim ~~40~~⁴ wherein said IFN- γ is administered following primary angioplasty for the treatment of acute myocardial infarction.

49-59. (Canceled)